The rationale behind the simultaneous use of those agents relies on the fact that both BCR and BRD2/BRD4 activity promote the activation of IKK, an apical kinase of the NF-κB pathway known to be over-activated in ABC-DLBCL. This evidence concerns the gene NFKB1 and aneurysmal bone cyst.